High-dose (200 mg/m 2 , MEL200) and intermediate-dose melphalan (100 mg/ m 2 , MEL100) showed significant activity in myeloma. In a phase 3 study, 298 patients were randomly assigned to receive 2 autologous transplantations after conditioning with MEL200 or MEL100. Ninetysix of 149 (64%) completed MEL200 and 103 of 149 (69%) MEL100. Best response to MEL200 was: complete remission 22 of 149 (15%); partial remission 95 of 149 (64%), for an overall response rate of 79%. Best response to MEL100 was: complete remission 12 of 149 (8%); partial remission 95 of 149 (64%), for an overall response rate of 72%. Overall survival did not differ (P ؍ .13); median progression-free survival (31.4 vs 26.2 months, P ؍ .01), median time to progression (34.4 vs 27.0 months, P ؍ .014) were longer in the MEL200. Treatment-related mortality was 3.1% in the MEL200 and 2.9% in the MEL100 group. Severe neutropenia and infections were marginally superior, whereas severe thrombocytopenia, mucositis, gastrointestinal adverse events, and the overall occurrence of at least 1 nonhematologic grade 3 or 4 adverse event were significantly higher in the MEL200 cohort. We conclude that MEL200 leads to longer remission duration and should be considered the standard conditioning regimen for autologous transplantation. This study was registered at www.clinicaltrials.gov as #NCT00950768.
IntroductionSeveral studies support the benefit of high-dose melphalan with stem cell rescue in patients with newly diagnosed multiple myeloma. [1][2][3] Results from randomized trials are in favor of tandem autologous transplantation rather than only 1 procedure, even though a real benefit remains to be determined. 4,5 Most conditioning regimens have been based on either melphalan alone or in combination with other agents. Melphalan at 200 mg/m 2 (MEL200) is considered the standard dose for conditioning patients younger than 65 years. 6 Older age and comorbidities may become limiting factors. In a retrospective case-matched study, 90 newly diagnosed patients treated with 2 courses of melphalan at 100 mg/m 2 (MEL100) were compared with a control group of 90 pair mates, matched for serum -microglobulin levels and Durie-Salmon clinical stage, and treated up-front with 2 MEL200 courses. 7 Median progression-free survival (PFS) was significantly superior in the MEL200 group, but overall survival (OS) was not different. Moreover, hematologic and nonhematologic toxicities were significantly reduced in the MEL100 group. Here, we report a phase 3 clinical trial comparing 2 doses of melphalan, MEL200 versus MEL100, in newly diagnosed multiple myeloma. The underlying hypothesis was that rather than give 2 very intensive preparative regimens before autologous stem cell infusions, providing effective myeloma cell kill, a less toxic reducedintensity conditioning would be better tolerated, especially in older patients, and equally effective.
Methods
PatientsFrom October 2001 to July 2006, 298 newly diagnosed myeloma patients younger than 65 years were enrolled in a prospecti...